Literature DB >> 22807175

Contrasting treatment-specific survival using double-robust estimators.

Min Zhang1, Douglas E Schaubel.   

Abstract

In settings where a randomized trial is infeasible, observational data are frequently used to compare treatment-specific survival. The average causal effect (ACE) can be used to make inference regarding treatment policies on patient populations, and a valid ACE estimator must account for imbalances with respect to treatment-specific covariate distributions. One method through which the ACE on survival can be estimated involves appropriately averaging over Cox-regression-based fitted survival functions. A second available method balances the treatment-specific covariate distributions through inverse probability of treatment weighting and then contrasts weighted nonparametric survival function estimators. Because both methods have their advantages and disadvantages, we propose methods that essentially combine both estimators. The proposed methods are double robust, in the sense that they are consistent if at least one of the two working regression models (i.e., logistic model for treatment and Cox model for death hazard) is correct. The proposed methods involve estimating the ACE with respect to restricted mean survival time, defined as the area under the survival curve up to some prespecified time point. We derive and evaluate asymptotic results through simulation. We apply the proposed methods to estimate the ACE of donation-after-cardiac-death kidney transplantation with the use of data obtained from multiple centers in the Netherlands.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22807175      PMCID: PMC4180679          DOI: 10.1002/sim.5511

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

1.  Causal inference on the difference of the restricted mean lifetime between two groups.

Authors:  P Y Chen; A A Tsiatis
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

2.  Adjusted survival curves with inverse probability weights.

Authors:  Stephen R Cole; Miguel A Hernán
Journal:  Comput Methods Programs Biomed       Date:  2004-07       Impact factor: 5.428

3.  Regression analysis of restricted mean survival time based on pseudo-observations.

Authors:  Per Kragh Andersen; Mette Gerster Hansen; John P Klein
Journal:  Lifetime Data Anal       Date:  2004-12       Impact factor: 1.588

4.  Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data.

Authors:  Jun Xie; Chaofeng Liu
Journal:  Stat Med       Date:  2005-10-30       Impact factor: 2.373

5.  Doubly robust estimation in missing data and causal inference models.

Authors:  Heejung Bang; James M Robins
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

Review 6.  Pseudo-observations in survival analysis.

Authors:  Per Kragh Andersen; Maja Pohar Perme
Journal:  Stat Methods Med Res       Date:  2009-08-04       Impact factor: 3.021

7.  Comment: Demystifying Double Robustness: A Comparison of Alternative Strategies for Estimating a Population Mean from Incomplete Data.

Authors:  Anastasios A Tsiatis; Marie Davidian
Journal:  Stat Sci       Date:  2007       Impact factor: 2.901

8.  Use of Irwin's restricted mean as an index for comparing survival in different treatment groups--interpretation and power considerations.

Authors:  T G Karrison
Journal:  Control Clin Trials       Date:  1997-04

9.  Kidneys from donors after cardiac death provide survival benefit.

Authors:  Maarten G Snoeijs; Douglas E Schaubel; Ronald Hené; Andries J Hoitsma; Mirza M Idu; Jan N Ijzermans; Rutger J Ploeg; Jan Ringers; Maarten H Christiaans; Wim A Buurman; L W Ernest van Heurn
Journal:  J Am Soc Nephrol       Date:  2010-05-20       Impact factor: 10.121

10.  Survival benefit-based deceased-donor liver allocation.

Authors:  D E Schaubel; M K Guidinger; S W Biggins; J D Kalbfleisch; E A Pomfret; P Sharma; R M Merion
Journal:  Am J Transplant       Date:  2009-04       Impact factor: 8.086

View more
  11 in total

1.  Adjusted restricted mean survival times in observational studies.

Authors:  Sarah C Conner; Lisa M Sullivan; Emelia J Benjamin; Michael P LaValley; Sandro Galea; Ludovic Trinquart
Journal:  Stat Med       Date:  2019-05-22       Impact factor: 2.373

2.  ON ESTIMATION OF THE OPTIMAL TREATMENT REGIME WITH THE ADDITIVE HAZARDS MODEL.

Authors:  Suhyun Kang; Wenbin Lu; Jiajia Zhang
Journal:  Stat Sin       Date:  2018-07       Impact factor: 1.261

3.  Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.

Authors:  Sébastien Bailly; Olivier Leroy; Philippe Montravers; Jean-Michel Constantin; Hervé Dupont; Didier Guillemot; Olivier Lortholary; Jean-Paul Mira; Pierre-François Perrigault; Jean-Pierre Gangneux; Elie Azoulay; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2015-09-14       Impact factor: 17.440

4.  A log rank type test in observational survival studies with stratified sampling.

Authors:  Xiaofei Bai; Anastasios A Tsiatis
Journal:  Lifetime Data Anal       Date:  2015-05-30       Impact factor: 1.588

5.  Landmark estimation of survival and treatment effects in observational studies.

Authors:  Layla Parast; Beth Ann Griffin
Journal:  Lifetime Data Anal       Date:  2016-02-15       Impact factor: 1.588

6.  Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.

Authors:  Amar U Kishan; R Jeffrey Karnes; Tahmineh Romero; Jessica K Wong; Giovanni Motterle; Jeffrey J Tosoian; Bruce J Trock; Eric A Klein; Bradley J Stish; Robert T Dess; Daniel E Spratt; Avinash Pilar; Chandana Reddy; Rebecca Levin-Epstein; Trude B Wedde; Wolfgang A Lilleby; Ryan Fiano; Gregory S Merrick; Richard G Stock; D Jeffrey Demanes; Brian J Moran; Michelle Braccioforte; Hartwig Huland; Phuoc T Tran; Santiago Martin; Rafael Martínez-Monge; Daniel J Krauss; Eyad I Abu-Isa; Ridwan Alam; Zeyad Schwen; Albert J Chang; Thomas M Pisansky; Richard Choo; Daniel Y Song; Stephen Greco; Curtiland Deville; Todd McNutt; Theodore L DeWeese; Ashley E Ross; Jay P Ciezki; Paul C Boutros; Nicholas G Nickols; Prashant Bhat; David Shabsovich; Jesus E Juarez; Natalie Chong; Patrick A Kupelian; Anthony V D'Amico; Matthew B Rettig; Alejandro Berlin; Jonathan D Tward; Brian J Davis; Robert E Reiter; Michael L Steinberg; David Elashoff; Eric M Horwitz; Rahul D Tendulkar; Derya Tilki
Journal:  JAMA Netw Open       Date:  2021-07-01

7.  Association between treatment of superficial bladder cancer and 10-year mortality in older adults with multiple chronic conditions.

Authors:  Tullika Garg; Amanda J Young; Maureen O'Keeffe-Rosetti; Carmit K McMullen; Matthew E Nielsen; H Lester Kirchner; Terrence E Murphy
Journal:  Cancer       Date:  2018-10-05       Impact factor: 6.921

8.  A Reassessment of the Survival Advantage of Simultaneous Kidney-Pancreas Versus Kidney-Alone Transplantation.

Authors:  Randall S Sung; Min Zhang; Douglas E Schaubel; Xu Shu; John C Magee
Journal:  Transplantation       Date:  2015-09       Impact factor: 4.939

9.  Observational Studies of Drug Safety in Multi-Database Studies: Methodological Challenges and Opportunities.

Authors:  Robert W Platt; Colin R Dormuth; Dan Chateau; Kristian Filion
Journal:  EGEMS (Wash DC)       Date:  2016-05-18

10.  Doubly robust estimator of risk in the presence of censoring dependent on time-varying covariates: application to a primary prevention trial for coronary events with pravastatin.

Authors:  Takuya Kawahara; Tomohiro Shinozaki; Yutaka Matsuyama
Journal:  BMC Med Res Methodol       Date:  2020-07-31       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.